利图西马布作为TNF抑制剂诱导的IgA血管炎与严重脏干扰的可能治疗方法
Agnieszka Przygocka1, Gian Marco Berti1, Anita Campus1
1Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy, Via Giuseppe Massarenti 9, Bologna, Italy.
BMC nephrology
|December 21, 2023
概括
瘤坏死因子 (TNF) 抑制剂可以引起药物诱导的血管炎,影响脏. 皮质类固醇和修复药对治疗这种罕见但严重的疾病有前途.
科学领域:
- 类风湿病学 类风湿病学
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
背景情况:
- 瘤亡因子 (TNF) 抑制剂越来越多地用于慢性炎症疾病,改善生活质量.
- 副作用,包括药物诱导的血管炎和脏干扰,随着使用范围的扩大而增加.
- 文献区分ANCA相关的血管炎和较罕见的免疫球蛋白A血管炎作为并发症.
研究的目的:
- 报告两例TNF抑制剂诱导的血管炎与严重的功能障碍.
- 为了突出利图西马布在治疗药物诱导的IgA血管炎与脏参与方面的疗效.
主要方法:
- 两名接受TNF抑制剂 (戈利穆马布,阿达利穆马布) 治疗的患者的病例报告经历了急性损伤和蛋白尿症.
- 脏活检证实了两位患者的IgA血管炎.
- 治疗包括皮质类固醇和rituximab.
主要成果:
- 两名患者都显示功能严重急性恶化和蛋白尿.
- 一名患者需要透析,在阿达利穆马布重新调试后出现了复发.
- 在这两种病例中,用皮质类固醇和修复剂成功治疗.
结论:
- 这是第一个关于rituximab用于药物诱导的IgA血管炎与脏参与的报告.
- 皮质类固醇和Rituximab为由于血管炎导致的功能衰竭提供了有效的治疗选择.
- 需要进一步的研究,但病例报告指导这种罕见疾病的管理.
关键词:
急性损伤是什么?急性损伤是什么?这就是Adalimumab.药物诱导的血管炎戈利慕姆巴布 (Golimumab) 是一个非常古老的生物.在 IgA 血管炎.里图西马布 (Rituximab) 是一种药物.瘤坏死因子抑制剂的使用更多相关视频
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
141
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:29Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145